RESEARCH TRIANGLE–Nobex, a drug development company, says it has appointed Russell M. Savre to the position of vice president of finance and administration.

Savre replaces Chuck Osborne, who resigned to become chief financial officer of Scynexis.

Savre was recently senior VP and chief financial officer of A.M. Pappas & Associates and brings 30 years of operational, managerial, and financial experience to the company.

Simultaneously, NOBEX announced today a business alliance with Fulcrum
Pharma Developments, a public UK company that offers a unique strategic drug development service that has been shown to reduce both development costs and times. Fulcrum leverages the expertise and experience of its seasoned drug development staff to provide customized programs that are designed to lead to early proof of concept, efficient registration and ideal positioning for rapid market.